CD19与BCMA双靶向CAR-T细胞共输注治疗难治性系统性红斑狼疮:1期试验
在难治性系统性红斑狼疮患者中,外周CD19⁺B细胞与骨髓CD19⁻BCMA⁺长寿命浆细胞是主要自身抗体来源,据此开展共输注自体抗CD19与抗BCMA CAR-T细胞的1期剂量递增试验。15例患者中位随访712天,无剂量限制性毒性,86.7%发生1级细胞因子释放综合征,12周时80%同时达到LLDAS与DORIS缓解。
要点
- 共输注抗CD19与抗BCMA CAR-T细胞在难治性SLE中未观察到剂量限制性毒性。
- 86.7%患者发生1级细胞因子释放综合征,无神经毒性和治疗相关死亡。
- 12周时15例中12例(80%)同时满足LLDAS和DORIS缓解标准。
核心结论
- 双靶向抗CD19/抗BCMA CAR-T细胞疗法在难治性SLE中显示出良好安全性和有希望的临床疗效。
- 本研究支持进一步开发该治疗方法用于难治性SLE患者。
研究设计与样本
- 正在进行的1期剂量递增试验,共输注自体抗CD19和抗BCMA CAR-T细胞,输注前接受氟达拉滨/环磷酰胺清淋。
- 队列包括15例患者(14例女性,1例男性)。
- 主要终点为28天内剂量限制性毒性和12周内不良事件;关键次要终点为12周内达到LLDAS和DORIS缓解及24周内CAR-T体内存续。
主要发现
- 中位随访712天(范围613-1,134天),未发生剂量限制性毒性。
- 86.7%患者发生1级细胞因子释放综合征,无神经毒性或治疗相关死亡。
- 最常见的3级或以上不良事件为中性粒细胞减少(100%)、血小板减少(40%)和贫血(13.3%),均可通过支持治疗逆转。
- 第12周时,15例患者中12例(80%)同时满足LLDAS和DORIS缓解标准。
- 多组学分析证实自身反应性CD19⁺BCMA⁺克隆被清除、初始IgM/IgD B细胞重建以及干扰素刺激和BAFF依赖特征持续下调。
关键数值与推荐
- 主要终点:28天内剂量限制性毒性、12周内不良事件。
- 关键次要终点:12周内LLDAS和DORIS缓解、24周内CAR-T体内存续。
- 探索性终点:输注后B细胞清除持续时间及恢复时间、免疫重建动力学以及自身抗体滴度和血清免疫球蛋白浓度的纵向变化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) remains refractory to conventional immunosuppression in a subset of patients. In treatment-refractory SLE, we show that peripheral CD19⁺ B cells and bone marrow CD19⁻BCMA⁺ long-lived plasma cells are dominant autoantibody sources, motivating dual CD19 and BCMA targeting. Here we report results from a cohort of patients (14 female, one male) in an ongoing phase 1 dose-escalation trial of co-infused autologous anti-CD19 and anti-BCMA chimeric antigen receptor (CAR) T cells after fludarabine/cyclophosphamide lymphodepletion. Primary endpoints were dose-limiting toxicities (DLTs) within 28 days and adverse events within 12 weeks; key secondary endpoints comprised attainment of Lupus Low Disease Activity State (LLDAS) and DORIS remission within 12 weeks and in vivo CAR-T persistence within 24 weeks. Exploratory endpoints were the duration of post-infusion B cell depletion and time to recovery, the kinetics of immune reconstitution and longitudinal changes in autoantibody titers and serum immunoglobulin concentrations after CAR-T therapy. Over a median 712-day follow-up (range, 613-1,134), no DLTs occurred. Grade 1 cytokine release syndrome developed in 86.7% of patients, with no neurotoxicity or treatment-related deaths. The most common grade 3 or higher adverse events were neutropenia (100%), thrombocytopenia (40%) and anemia (13.3%), all of which were reversible with supportive care. By week 12, 12 of 15 patients (80%) fulfilled both the LLDAS and DORIS remission criteria. Multiomic analyses confirmed elimination of autoreactive CD19⁺BCMA⁺ clones, reconstitution of naive IgM/IgD B cells and durable downregulation of interferon-stimulated and BAFF-dependent signatures, indicating improved immune homeostasis. Longitudinal monitoring of three patients for 1 year demonstrated sustained eradication of pathogenic clones, suggesting potential cure. Dual anti-CD19/anti-BCMA CAR-T cell therapy demonstrates good safety and promising clinical efficacy in treatment-refractory SLE. This study supports the further development of this treatment approach for patients with rSLE. ClinicalTrials.gov identifier: NCT05030779 .
引用
- Feng J, Huo D, Hong R, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025. PMID: 40993243. doi:10.1038/s41591-025-03937-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。